Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Diffusion gradient

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    6 result(s) found for: Diffusion gradient. Displaying page 1 of 1.
    EudraCT Number: 2019-002075-33 Sponsor Protocol Number: ENRICH-AF Start Date*: 2020-05-05
    Sponsor Name:Hamilton Health Sciences, through its Population Health Research Institute
    Full Title: Edoxaban for intracranial hemorrhage survivors with atrial fibrillation
    Medical condition: High risk atrial fibrillation patients with previous intracranial hemorrhage
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10018985 Haemorrhage intracranial PT
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NO (Prematurely Ended) DE (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) BE (Trial now transitioned) CZ (Trial now transitioned) AT (Trial now transitioned) IT (Trial now transitioned) SK (Trial now transitioned) DK (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-003492-35 Sponsor Protocol Number: MED2-201301 Start Date*: 2015-05-26
    Sponsor Name:University of Bonn
    Full Title: Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation with Dabigatran after Pulmonary Vein Isolation for Atrial Fibrillation
    Medical condition: atrial fibriallation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001254-22 Sponsor Protocol Number: SARPAC Start Date*: 2020-03-24
    Sponsor Name:University Hospital Ghent
    Full Title: A prospective, randomized, open-label, interventional study to investigate the efficacy of sargramostim (Leukine®) in improving oxygenation and short- and long-term outcome of COVID-19 patients wit...
    Medical condition: Acute hypoxic respiratory failure of COVID-19 patients
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10074615 Hypoxic respiratory failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001853-15 Sponsor Protocol Number: NL61830 Start Date*: 2018-07-11
    Sponsor Name:Leiden University Medical Center
    Full Title: An explorative study for halting inflammation in patients with emphysema by intravenous administration of autologous bone marrow derived mesenchymal stromal cells.
    Medical condition: Pulmonary emphysema
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001088-26 Sponsor Protocol Number: MN42928 Start Date*: 2021-12-21
    Sponsor Name:F. HOFFMANN - LA ROCHE LTD.
    Full Title: SAKURABONSAI: CLINICAL, IMAGING AND BIOMARKER OPEN-LABEL STUDY IN NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) WITH SATRALIZUMAB AS AN INTERVENTION
    Medical condition: Neuromyelitis Optica Spectrum Disorder (NMOSD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10077875 Neuromyelitis optica spectrum disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) FR (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005555-27 Sponsor Protocol Number: ESR-14-10473 Start Date*: 2017-09-12
    Sponsor Name:University Hospital Basel
    Full Title: Prevention of Cerebral Ischaemia in Stent Treatment for Carotid Artery Stenosis - A randomised multi-centre phase II trial comparing Ticagrelor versus Clopidogrel with outcome assessment on MRI (PR...
    Medical condition: Carotid artery stenting (CAS) is treatment for atherosclerotic carotid stenosis. The main adverse events are thromboembolic brain infarcts during the procedure. Ticagrelor, a novel reversible inhib...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) BE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 05 13:09:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA